Rekah Pharmaceutical Industry Ltd. (REKA.TA)
ILA 1176.0
(-1.26%)
ILA 1176.0
(-1.26%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 26.02 Million ILS | -35.32% |
| 2022 | 40.23 Million ILS | 10.57% |
| 2021 | 36.2 Million ILS | -9.04% |
| 2020 | 39.68 Million ILS | 47.64% |
| 2019 | 26.55 Million ILS | 7.85% |
| 2018 | 26.41 Million ILS | 9.47% |
| 2017 | 22.95 Million ILS | 29.64% |
| 2016 | 17.7 Million ILS | 23.34% |
| 2015 | 14.35 Million ILS | 5.23% |
| 2014 | 13.64 Million ILS | -2.21% |
| 2013 | 25.28 Million ILS | -28.57% |
| 2012 | 19.53 Million ILS | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 11.2 Million ILS | 1075.55% |
| 2024 Q2 | 26.29 Million ILS | 134.7% |
| 2023 Q2 | 9.26 Million ILS | -12.89% |
| 2023 Q1 | 10.63 Million ILS | 21.4% |
| 2023 Q4 | 953 Thousand ILS | -82.72% |
| 2023 FY | - ILS | -35.32% |
| 2023 Q3 | 5.51 Million ILS | -40.46% |
| 2022 Q3 | 10.5 Million ILS | 6.98% |
| 2022 FY | - ILS | 10.57% |
| 2022 Q1 | 11.15 Million ILS | 2.93% |
| 2022 Q2 | 9.81 Million ILS | -12.01% |
| 2022 Q4 | 8.76 Million ILS | -16.58% |
| 2021 Q1 | 9.31 Million ILS | 11.31% |
| 2021 Q4 | 10.83 Million ILS | 42.47% |
| 2021 Q3 | 7.6 Million ILS | -9.82% |
| 2021 FY | - ILS | -9.04% |
| 2021 Q2 | 8.43 Million ILS | -9.48% |
| 2020 Q2 | 9.18 Million ILS | -8.16% |
| 2020 Q1 | 10 Million ILS | 176.63% |
| 2020 FY | - ILS | 47.64% |
| 2020 Q4 | 8.37 Million ILS | -31.11% |
| 2020 Q3 | 12.15 Million ILS | 32.28% |
| 2019 Q1 | 7.54 Million ILS | 98.03% |
| 2019 FY | - ILS | 7.85% |
| 2019 Q4 | 3.61 Million ILS | -57.75% |
| 2019 Q3 | 8.55 Million ILS | 27.39% |
| 2019 Q2 | 6.71 Million ILS | -10.99% |
| 2018 Q4 | 3.81 Million ILS | -36.05% |
| 2018 FY | - ILS | 9.47% |
| 2018 Q1 | 7.7 Million ILS | 140.22% |
| 2018 Q2 | 7.64 Million ILS | -0.71% |
| 2018 Q3 | 5.96 Million ILS | -22.07% |
| 2017 FY | - ILS | 29.64% |
| 2017 Q1 | 4.77 Million ILS | 636.42% |
| 2017 Q2 | 8.84 Million ILS | 85.44% |
| 2017 Q3 | 6.12 Million ILS | -30.79% |
| 2017 Q4 | 3.2 Million ILS | -47.63% |
| 2016 Q2 | 6.09 Million ILS | 4.13% |
| 2016 FY | - ILS | 23.34% |
| 2016 Q1 | 5.85 Million ILS | 5.63% |
| 2016 Q4 | 648 Thousand ILS | -87.3% |
| 2016 Q3 | 5.1 Million ILS | -16.36% |
| 2015 FY | - ILS | 5.23% |
| 2015 Q4 | 5.54 Million ILS | -13.99% |
| 2015 Q3 | 6.44 Million ILS | 388.78% |
| 2015 Q2 | 1.31 Million ILS | -51.9% |
| 2015 Q1 | 2.74 Million ILS | 185.58% |
| 2014 Q2 | 3.97 Million ILS | -32.09% |
| 2014 Q4 | -3.2 Million ILS | -153.64% |
| 2014 FY | - ILS | -2.21% |
| 2014 Q3 | 5.97 Million ILS | 50.45% |
| 2014 Q1 | 5.84 Million ILS | 325.89% |
| 2013 FY | - ILS | -28.57% |
| 2013 Q2 | 3.75 Million ILS | 137.7% |
| 2013 Q3 | 3.4 Million ILS | -9.42% |
| 2013 Q4 | -2.58 Million ILS | -176.03% |
| 2013 Q1 | 1.58 Million ILS | -66.5% |
| 2012 Q4 | 4.71 Million ILS | 13.3% |
| 2012 Q3 | 4.16 Million ILS | 0.0% |
| 2012 FY | - ILS | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Cannabotech LTD | -14.81 Million ILA | 275.733% |